These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 16203654)

  • 1. Effects of drospirenone/estrogen combinations on bone metabolism.
    Christiansen C
    Climacteric; 2005 Oct; 8 Suppl 3():35-41. PubMed ID: 16203654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy.
    Oelkers WH
    Climacteric; 2005 Oct; 8 Suppl 3():19-27. PubMed ID: 16203652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Added benefits of drospirenone for compliance.
    Foidart JM
    Climacteric; 2005 Oct; 8 Suppl 3():28-34. PubMed ID: 16203653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levonorgestrel and 17beta-estradiol given transdermally for the prevention of postmenopausal osteoporosis.
    Warming L; Ravn P; Christiansen C
    Maturitas; 2005 Feb; 50(2):78-85. PubMed ID: 15653003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of drospirenone used in a continuous combination with 17beta-estradiol for prevention of postmenopausal osteoporosis.
    Warming L; Ravn P; Nielsen T; Christiansen C
    Climacteric; 2004 Mar; 7(1):103-11. PubMed ID: 15259289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in hormone replacement therapy: weight benefits of drospirenone, a 17alpha-spirolactone-derived progestogen.
    Foidart JM; Faustmann T
    Gynecol Endocrinol; 2007 Dec; 23(12):692-9. PubMed ID: 18075844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
    Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
    Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.
    Dane C; Dane B; Cetin A; Erginbas M
    Gynecol Endocrinol; 2007 Jul; 23(7):398-403. PubMed ID: 17701771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects.
    Greenwald MW; Gluck OS; Lang E; Rakov V
    Menopause; 2005; 12(6):741-8. PubMed ID: 16278618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial.
    Archer DF; Thorneycroft IH; Foegh M; Hanes V; Glant MD; Bitterman P; Kempson RL
    Menopause; 2005; 12(6):716-27. PubMed ID: 16278615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, placebo-controlled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide.
    Preston RA; Norris PM; Alonso AB; Ni P; Hanes V; Karara AH
    Menopause; 2007; 14(3 Pt 1):408-14. PubMed ID: 17224857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of two low-dose combined oral contraceptives containing drospirenone on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study.
    Gargano V; Massaro M; Morra I; Formisano C; Di Carlo C; Nappi C
    Contraception; 2008 Jul; 78(1):10-5. PubMed ID: 18555812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism.
    Palacios S; Foidart JM; Genazzani AR
    Maturitas; 2006 Nov; 55(4):297-307. PubMed ID: 16949774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of 17beta-oestradiol plus different doses of drospirenone on adipose tissue, adiponectin and atherogenic metabolites in postmenopausal women.
    Tankó LB; Christiansen C
    J Intern Med; 2005 Dec; 258(6):544-53. PubMed ID: 16313478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial.
    Ettinger B; Ensrud KE; Wallace R; Johnson KC; Cummings SR; Yankov V; Vittinghoff E; Grady D
    Obstet Gynecol; 2004 Sep; 104(3):443-51. PubMed ID: 15339752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of an oral contraceptive containing drospirenone on bone turnover and bone mineral density.
    Nappi C; Di Spiezio Sardo A; Greco E; Tommaselli GA; Giordano E; Guida M
    Obstet Gynecol; 2005 Jan; 105(1):53-60. PubMed ID: 15625142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drospirenone in HRT?
    Drug Ther Bull; 2009 Apr; 47(4):41-4. PubMed ID: 19357298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect on cartilage of different forms of application of postmenopausal estrogen therapy: comparison of oral and transdermal therapy.
    Ravn P; Warming L; Christgau S; Christiansen C
    Bone; 2004 Nov; 35(5):1216-21. PubMed ID: 15542048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drospirenone--a new progestogen with antimineralocorticoid activity, resembling natural progesterone.
    Oelkers W
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():17-24. PubMed ID: 11246598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nomegestrol acetate may enhance the skeletal effects of estradiol on biochemical markers of bone turnover in menopausal women after a 12-week treatment period.
    Nguyên-Pascal ML; Thomas JL; Bergougnoux L; Garnero P; Drapier-Faure E; Delmas PD
    Climacteric; 2005 Jun; 8(2):136-45. PubMed ID: 16096169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.